Is this medical advice?

No. This tool is for information only and is not medical advice or a recommendation to start, stop, or switch any treatment. Every treatment decision should go through your nephrologist.

How do I join a clinical trial?

Each listed trial links to its ClinicalTrials.gov page, which has contact details and eligibility criteria. Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.

Are these all the treatments available?

No. The treatment list highlights newer and recently approved therapies, not the full standard of care. Foundational first-line care (such as blood-pressure control and SGLT2 inhibitors) is shown separately, and your care team may recommend other options.

Free tool · No signup

Kidney disease treatment & trial finder

Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.

For information only — not medical advice. Always talk to your nephrologist.

Kidney treatment is advancing fast

17 FDA-approved therapies since 2018 — 8 in the last two years — plus 3 trials enrolling now.

Approved therapies

Trials enrolling

Conditions covered

’18

’19

’20

’21

’22

’23

’24

’25

’26

New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.

Select your kidney diagnosis

Type

Common conditions

Treatment Options for Your Diagnosis

Foundational care

Start here

Blood-pressure control with ACE inhibitors or ARBs, and SGLT2 inhibitors, are standard first-line therapy for most CKD. Your nephrologist typically starts here.

These are newer and recently approved therapies for Membranous nephropathy — not the full standard of care. Ask your care team whether any fit your situation.

Genentech / Roche

Rituximab (Rituxan)

FDA approved (used off-label)

Anti-CD20 B-cell depleting antibody

MENTOR

Evidence: Superior remission and anti-PLA2R antibody depletion vs cyclosporine at 24 months.

View the MENTOR study on ClinicalTrials.gov

Source: MENTOR trial, NEJM 2019 (rituximab is not FDA-labeled for this use)Verified 2026-07-18

Clinical Trials Related to Your Diagnosis

Actively enrolling studies related to Membranous nephropathy. Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.

Biogen

Felzartamab

Enrolling

PROMINENTPhase 3

Testing felzartamab (an anti-CD38 antibody) against tacrolimus in adults with primary (anti-PLA2R) membranous nephropathy. Earlier-phase data showed rapid anti-PLA2R antibody reductions.

Eligibility is determined by the study team and your nephrologist.

View the PROMINENT on ClinicalTrials.gov

Source: M-PLACE Phase 2 data (Biogen)Verified 2026-07-18

Browse all recruiting Membranous nephropathy trials on ClinicalTrials.gov

For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.

Conditions covered

Jump straight to treatments and enrolling trials for a specific kidney diagnosis.

Diabetic kidney disease (diabetic nephropathy)3 treatments IgA nephropathy (Berger disease)6 treatments FSGS (focal segmental glomerulosclerosis)1 treatment Membranous nephropathy1 treatment · 1 trial Membranoproliferative GN / C3 glomerulopathy2 treatments Lupus nephritis3 treatments · 1 trial ANCA-associated vasculitis / rapidly progressive GN1 treatment Polycystic kidney disease1 treatment APOL1-mediated kidney disease1 trial

Manage your whole kidney journey

Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.

Get started free